Guerbet : Q4 2023: sharp recovery (as expected) giving greater credence to 2024e guidance – Estimates raised – TP & rating raised to Outperform (vs Neutral)
>Q4 2023 sales: the Raleigh site delivered / momentum turning favourable - Q4 sales came to € 211.8m, up +15.1% and +17.9% at cc. Over the full year 2024, sales reached € 785.7m (+4.3%, +6.4% at cc and +5.9% excluding Intrasense), with EMEA at +6% at cc (price effect and normalisation of capacity to produce/deliver), ASPAC at +15.9% (market share gains, volume effect and pick-up in direct business), Americas at -1.4% (low level of deliveries in H1). Guerbet said that...Guerbet is a French pharmaceutical group that develops, markets, and provides maintenance services for medical equipment and devices destined for diagnostic and interventional imaging. Co.'s portfolio comprises media solutions covering MRI, X-rays and products devoted to International Radiology and Theranostics and medical devices. Co. organizes its operation by product family covering Magnetic Resonance Imaging (MRI), X-rays (XR) and Interventional Radiology and Theranostics (IRT). The MRI family includes Dotarem® and Artirem®; Co.'s X-ray product family includes Xenetix®, Optiray®/Optiject®, Oxilan®, and Telebrix®; and the IRT product family has Lipiodol®, Bleu Patente V and Hexabrix®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.